EMEA-000118-PIP01-07-M01

Key facts

Invented name
Orencia
Active substance
Abatacept
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/100/2009
PIP number
EMEA-000118-PIP01-07-M01
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
  • Juvenile Arthritis
  • Rheumatoid arthritis
Route(s) of administration
Intravenous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG
medinfo.emea@bms.com
United Kingdom
+44 1895 52 37 40
+44 1895 52 36 77
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number
EMEA-C-000118-PIP01-07-M01
Compliance opinion date
29/05/2009
Compliance outcome
positive

Decision

How useful was this page?

Add your rating